Chlorpromazine and QX222 block 5-HT3 receptors in N1E-115 neuroblastoma cells

Neuropharmacology. 1994 Mar-Apr;33(3-4):493-9. doi: 10.1016/0028-3908(94)90080-9.

Abstract

The effects of chlorpromazine and the lidocaine derivative QX222, which block nicotinic acetylcholine receptors, were examined on 5-HT3 receptors in N1E-115 mouse neuroblastoma cells, using whole cell voltage-clamp and radioligand binding. Electrophysiological studies examining the effects of chlorpromazine and QX222 on 5-HT3 agonist-induced responses revealed IC50s of 0.2 and 8.5 microM respectively. The action was not voltage- or use-dependent and there was no blocking action when chlorpromazine was applied from inside the cell. Chlorpromazine and QX222 inhibited the binding of a radiolabelled 5-HT3 receptor antagonist, [3H]GR65630, with IC50s of 0.9 and 29 microM respectively. Scatchard plots revealed a decrease in affinity (Kd) in the presence of chlorpromazine, but no change in the maximum number of binding sites (Bmax). The results suggest differential actions of the compounds at 5-HT3 and acetylcholine receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Affinity Labels
  • Animals
  • Brain Neoplasms / metabolism*
  • Chlorpromazine / pharmacology*
  • Electrophysiology
  • Kinetics
  • Lidocaine / analogs & derivatives*
  • Lidocaine / pharmacology
  • Mice
  • Neuroblastoma / metabolism*
  • Patch-Clamp Techniques
  • Photochemistry
  • Receptors, Serotonin / drug effects*
  • Serotonin / physiology
  • Serotonin Antagonists / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Affinity Labels
  • Receptors, Serotonin
  • Serotonin Antagonists
  • QX-222
  • Serotonin
  • Lidocaine
  • Chlorpromazine